{"id":"W4385697375","doi":"10.1097/01.hs9.0000970688.75458.a8","title":"P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary; McGill University; University of Toronto; Jewish General Hospital; Institute of Cancer Research","funders":"","keywords":"Medicine; Tocilizumab; Internal medicine; Multiple myeloma; Cytokine release syndrome; Incidence (geometry); Refractory (planetary science); Gastroenterology; Immunotherapy; Chimeric antigen receptor; Rheumatoid arthritis; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002259849,0.0002681142,0.0009779703,0.0001593574,0.0001679945,0.0003966312,0.0002824404,0.0003862891,0.003075393],"category_scores_gemma":[0.0005607086,0.0001413798,0.0003797153,0.0001774501,0.0001560088,0.0001983547,0.000157421,0.0008559553,0.0004099184],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000334343,"about_ca_system_score_gemma":0.0004543595,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006440323,"about_ca_topic_score_gemma":0.001783504,"domain_scores_codex":[0.999874,0.00003701245,0.000009443491,0.00002174383,0.00002293745,0.00003489471],"domain_scores_gemma":[0.9998162,0.00003469053,0.00004991298,0.00001006276,0.00001190179,0.00007721096],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.413927,0.01615083,0.0425184,0.0009688645,0.001218725,0.0004465881,0.000174948,0.001572508,0.09977423,0.0001439456,0.006338916,0.4167651],"study_design_scores_gemma":[0.1027997,0.4300718,0.4244617,0.0001524438,0.001806631,0.001694636,0.0001269887,0.003232265,0.02598285,0.0001711563,0.009450315,0.00004957938],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971268,0.001579944,0.00009143169,0.0001269106,0.00003872281,0.0001204916,0.000165545,0.00004180064,0.0007083631],"genre_scores_gemma":[0.998165,0.0004351295,0.000198799,0.000110748,0.00004266629,0.00009229068,0.0002793848,0.000004139665,0.0006718533],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003075393,"threshold_uncertainty_score":0.01028818,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0166835084563772,"score_gpt":0.2672355611624662,"score_spread":0.250552052706089,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}